Browse/search for people
Dr Sebastian Oltean
Dr Sebastian Oltean
MBBS (Cluj, Romania), PhD (Univ of Nebraska-Lincoln, USA)
My main research interests include the study of alternative splicing in vivo, coordinated regulation of alternative splicing in physiology and disease (with focus on cancer, chronic kidney diseases and diabetes) as well as manipulation of splice isoforms choice for therapeutic goals. Alternative splicing is the main process that decides the diversity of proteins in our bodies. It is estimated that more than 90% of genes are alternatively spliced in humans and therefore this process affects all cellular properties. The function of the majority of splicing isoforms is not characterized yet. Numerous splicing isoforms have been associated with disease progression in recent years and there is much interest in understanding their contribution to pathogenesis and how this can be reversed.
Sebastian studied clinical medicine at “Iuliu Hatieganu” Medical School, Cluj-Napoca, Romania and trained as a junior doctor in Nephrology and Dialysis before moving to USA where he obtained a PhD from the University of Nebraska-Lincoln in 2004.This was followed by postdoctoral training at Duke University Medical Center (North Carolina, USA) where he became interested in studying the connections between alternative splicing and cancer. Using fluorescent splicing reporters that recapitulate in vivo the alternative splicing of fibroblast growth factor 2 and are able to follow epithelial-mesenchymal transitions he discovered unusual plasticity in prostate cancer cells in animal models. This was further followed by studies of circulating tumour cells from patients showing that the same plasticity is associated with aggressive prostate and breast cancer behavior. In 2008 he moved to the University of Bristol where he is now a principal investigator and continues to study alternative splicing in vivo, with focus towards the importance of several genes splice isoforms (e.g VEGF, FGFR2) in cancer as well as kidney diseases and development of splice-based therapeutics.
MSc in Biomedical Sciences Research - Cancer Biology Unit 2 - Angiogenesis in Cancer
MB ChB Programme - year 2 - Renal System
BSc Health Sciences - Cell fate / cancer
BSc - Pharmacology 2A
- tumour biology
- kidney pathology
- alternative splicing
- novel therapeutics
- cancer (prostate cancer)
- chronic kidney diseases (diabetic nephropathy)
- Mavrou, A, Brakspear, K, Hamdollah-Zadeh, M, Damodaran, G, Babaei-Jadidi, R, Oxley, J, Gillatt, DA, Ladomery, MR, Harper, SJ, Bates, DO & Oltean, S, 2015, Serine–arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene.
- Oltean, S & Bates, DO, 2014, Hallmarks of alternative splicing in cancer. Oncogene, vol 33., pp. 5311-5318
- Oltean, S, Sorg, B, Albrecht, T, Bonano, V, Brazas, R, Dewhirst, M & Garcia-Blanco, M, 2006, Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. PNAS.
- Amin, E, Oltean, S, Hua, J, Gammons, M, Hamdollah-Zadeh, A, Welsh, G, Cheung, M, Ni, L, Kase, S, Rennel, E, Symonds, K, Nowak, D, Royer-Pokora, B, Saleem, M, Hagiwara, M, Schumacher, V, Harper, S, Hinton, D, Bates, D & Ladomery, M, 2011, WT1 Mutants Reveal SRPK1 to Be a Downstream Angiogenesis Target by Altering VEGF Splicing. Cancer Cell, vol 20., pp. 768 - 780
- Bonano, V, Oltean, S & Garcia-Blanco, M, 2007, A protocol for imaging alternative splicing regulation in vivo using fluorescence reporters in transgenic mice. Nature Protocols.
Read more >
- Bullock, N, Potts, J, Simpkin, AJ, Koupparis, A, Harper, SJ, Oxley, J & Oltean, S, 2016, Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion. Molecular Pathology, vol 69., pp. 171-5
- Stevens, M & Oltean, S, 2016, Alternative Splicing in CKD. Journal of the American Society of Nephrology.
- Oltean, S, Qiu, Y, Ferguson, JK, Stevens, M, Neal, C, Russell, A, Kaura, A, Arkill, KP, Harris, K, Symonds, C, Lacey, K, Wijeyaratne, L, Gammons, M, Wylie, E, Hulse, RP, Alsop, C, Cope, G, Damodaran, G, Betteridge, KB, Ramnath, R, Satchell, SC, Foster, RR, Ballmer-Hofer, K, Donaldson, LF, Barratt, J, Baelde, HJ, Harper, SJ, Bates, DO & Salmon, AHJ, 2015, Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy. Journal of the American Society of Nephrology, vol 26., pp. 1889-904
- Munkley, J, Oltean, S, Vodák, D, Wilson, BT, Livermore, KE, Zhou, Y, Star, E, Floros, VI, Johannessen, B, Knight, B, McCullagh, P, McGrath, J, Crundwell, M, Skotheim, RI, Robson, CN, Leung, HY, Harries, LW, Rajan, P, Mills, IG & Elliott, DJ, 2015, The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. Oncotarget, vol 6., pp. 34358-74
- Bunni, J, Shelley-Fraser, G, Stevenson, K, Oltean, S, Salmon, A, Harper, SJ, Carter, JG & Bates, DO, 2015, Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-Axxxb) in colorectal cancer patients predicts tumour VEGF-A ratios. American Journal of Cancer Research, vol 5., pp. 2083-9
Edit this profile If you are Dr Sebastian Oltean, you can edit this page. Login required.